PSMA PET scans to predict outcomes in newly diagnosed prostate cancer
Studies how well PSMA PET scans predict outcomes in newly diagnosed prostate cancer.
Plain-language title generated from the registry record
Registry title: A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Key facts
- Where
- Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, and Yinchuan, ChinaSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with newly diagnosed prostate cancer who have not had any treatment yet and had a PSMA PET scan before treatment.
- Age
- 18 to 100 years
- Sex
- Men only
- Disease stage
- Prostate cancer confirmed by a prostate biopsy, newly diagnosed. Neuroendocrine prostate cancer is not accepted.
- Earlier treatment
- No prostate cancer treatment before the PSMA PET scan. The scan must have been done as the first staging, before any treatment.
Main reasons for not taking part
- Any prostate cancer treatment before the PSMA PET scan
- Spread of another type of cancer (metastasized or disseminated malignancy other than prostate cancer)
- Neuroendocrine prostate cancer
- Fewer than 2 years of follow-up data on progression-free survival and overall survival
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07474142, who can take part
Where in China
- The First Hospital of Lanzhou UniversityLanzhou, ChinaContact: Wei ZhangTaking people
- Weinan Central HospitalWeinan, ChinaContact: Weihong Zhao, MD.Taking people
- Shaanxi provincial people's hospitalXi'an, ChinaContact: Yi Sun, MD.Taking people
- Xijing 986 HospitalXi'an, ChinaContact: Wuhe Zhang, MD.Taking people
- Xijing Hospital, Fourth Military Medical UniversityXi'an, ChinaContact: Jiao, MD.Taking people
- The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, ChinaContact: Wei Zheng, MD.Taking people
- Qinghai university affiliated hospitalXining, ChinaContact: Guojun Chen, MD.Taking people
- Affiliated Hospital of Yan'an UniversityYan’an, ChinaContact: Jixue Gao, MD.Taking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaContact: Zhiyong Lv, MD.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT07474142
- Record updated
- 16 March 2026
- Original description
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the mixture of different disease stages may compromise the accuracy of prognostic tools. This study aims to specifically investigate the prognostic value of initial staging PSMA PET for progression-free survival in patients with newly diagnosed, treatment-naïve prostate cancer, and to develop corresponding prognostic tools.Read full original descriptionShow less
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the mixture of different disease stages may compromise the accuracy of prognostic tools. This study aims to specifically investigate the prognostic value of initial staging PSMA PET for progression-free survival in patients with newly diagnosed, treatment-naïve prostate cancer, and to develop corresponding prognostic tools.
Need:
The prognostic value of initial staging with PSMA PET is needed for treatment management and study design.
Primary Outcome:
To assess the prognostic value of initial staging by PSMA PET: generate a prognostic tool (PSMA-VISION score) based on initial staging of PSMA PET to predict progression-free survival.
Secondary Outcomes:
To compare PSMA-VISION score with the other prognostic tools (such as NCCN, STARCAP, PPP nomogram, PPP2 nomogram, etc.) and to evaluate the prognostic value of initial staging by PSMA PET to predict overall survival (OS). The correlation with clinicopathological variables and prediction of early progression (Exploratory) was also investigated.
Inclusion:
1. Patients with pathologically confirmed prostate cancer by prostate biopsy. 2. Undergone PSMA PET examination as initial staging before any treatment. 3. Have at least 2 years of follow-up data for progression-free survival and overall survival.
Exclusion Criteria:
1. Patients undergone any prior prostate cancer treatment before undergoing PSMA PET imaging. 2. Patients with metastasized or disseminated malignancy other than prostate cancer 3. Patients with neuroendocrine prostate cancer.
Inclusion: Patients with pathologically confirmed prostate cancer by prostate biopsy; Undergone PSMA PET examination as initial staging before any treatment; Have at least 2 years of follow-up data for progression-free survival and overall survival.
Exclusion: Patients undergone any prior prostate cancer treatment before undergoing PSMA PET imaging; Patients with metastasized or disseminated malignancy other than prostate cancer; Patients with neuroendocrine prostate cancer.